Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia

Journal of the American Academy of Dermatology

Volumn 57, Issue 6 SUPPL., 2007, Pages

  Betts, Robert F ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; INJECTION SITE RASH; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VACCINATION; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; COMORBIDITY; COST OF ILLNESS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; MIDDLE AGED; NEURALGIA, POSTHERPETIC;

EID: 36048951028     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.09.017     Document Type: Article

References (19)

1. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., and Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 24 (2006) 1308-1314
2. Ragozzino M.W., Melton III L.J., Kurland L.T., Chu C.P., and Perry H.O. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61 (1982) 310-316
3. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58 (1965) 9-20
4. Lin F., and Hadler J.L. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 181 (2000) 1897-1905
5. Mounsey A.L., Matthew L.G., and Slawson D.C. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 72 (2005) 1075-1080
6. Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., and Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 330 (1994) 896-900
7. Whitley R.J., Weiss H., Gnann Jr. J.W., Tyring S., Mertz G.J., Pappas P.G., et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 125 (1996) 376-383
8. McDermott A.M., Toelle T.R., Rowbotham D.J., Schaefer C.P., and Dukes E.M. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 10 (2006) 127-135
9. Zostavax [zoster vaccine live (Oka/Merck)]. [package insert] (2006), Merck & Co., Inc, Whitehouse Station, NJ
10. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al., Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
11. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 5 (2004) 344-356
12. Oxman MN, Williams HM, Levin MJ, Johnson GR, Zhang JH, Schmader K, et al, for the Shingles Prevention Study Group. Efficacy of zoster vaccine according to dermatome region. Poster presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC.
13. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., and Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 20 (2005) 748-753
14. Schmader K. Herpes zoster in older adults. Clin Infect Dis 32 (2001) 1481-1486
15. Dworkin R.H., and Schmader K.E. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 36 (2003) 877-882
16. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 18 (2002) 350-354
17. Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention's advisory committee recommends "shingles" vaccination. Available at: http://www.cdc.gov/od/OC/media/pressrel/r861026.htm. Accessed October 15, 2007.
18. Nichol K.L. Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. Am J Med 105 (1998) 385-392
19. Nichol K.L., MacDonald R., and Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med 11 (1996) 673-677